4808 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 15
Brough et al.
picard.ch/downloads/Hsp90interactors.pdf. Accessed on July 13,
2009
(7) Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of
cancer. Nat. Rev. Cancer 2005, 5, 761–772.
(8) Maloney, A.; Workman, P. HSP90 as a new therapeutic target for
cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002,2,3–24.
(9) Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and diag-
nostic implications of Hsp90 activation. Trends Mol. Med. 2004,
10, 283–290.
allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock
protein 90. J. Natl. Cancer Inst. 1999, 91, 1940–1949.
(30) Meli, M.; Pennati, M.; Curto, M.; Daidone, M. G.; Plescia, J.;
Toba, S.; Altieri, D. C.; Zaffaroni, N.; Colombo, G. Small-Mole-
cule Targeting of Heat Shock Protein 90 Chaperone Function:
Rational Identification of a New Anticancer Lead. J. Med. Chem.
2006, 49, 7721–7730.
(31) Gaspar, N.; Sharp, S. Y.; Pacey, S.; Jones, D.; Walton, M.; Vassal,
G.; Eccles, S.; Pearson, A.; Workman, P. Acquired Resistance to
17-Allylamino-17-Demethoxygeldanamycin (Tanespimycin) in
Glioblastoma Cells. Cancer Res. 2009, 69, 1966–1975.
(10) Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Hsp90: the vulnerable
chaperone. Drug Discovery Today 2004, 9, 881–888.
(11) Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000,
100, 57–70.
(12) Workman, P. Combinatorial attack on multistep oncogenesis by
inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206,
149–157.
(32) Kaur, G.; Belotti, D.; Burger, A. M.; Fisher-Nielson, K.; Borsotti,
P.; Riccardi, E.; Thillainathan, J.; Hollingshead, M.; Sausville, E.
A.; Giavazzi, R. Antiangiogenic properties of 17-(dimethylam-
inoethylamino)-17-demethoxygeldanamycin: an orally bioavail-
able heat shock protein 90 modulator. Clin. Cancer Res. 2004, 10,
4813–4821.
(13) DeBoer, C.; Meulman, P. A.; Wnuk, R. J.; Peterson, D. H.
Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo) 1970, 23,
442–447.
(14) Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L.
Preclinical pharmacologic evaluation of geldanamycin as an anti-
tumor agent. Cancer Chemother. Pharmacol. 1995, 36, 305–315.
(15) Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a
potential anticancer agent: its molecular target and biochemical
activity. Invest. New Drugs 1999, 17, 361–373.
(33) Ge, J.; Normant, E.; Porter, J. R.; Ali, J. A.; Dembski, M. S.; Gao,
Y.; Georges, A. T.; Grenier, L.; Pak, R. H.; Patterson, J.; Sydor, J.
R.; Tibbitts, T. T.; Tong, J. K.; Adams, J.; Palombella, V. J. Design,
synthesis, and biological evaluation of hydroquinone derivatives of
17-amino-17-demethoxygeldanamycin as potent, water-soluble in-
hibitors of Hsp90. J. Med. Chem. 2006, 49, 4606–4615.
(34) Sydor, J. R.; Normant, E.; Pien, C. S.; Porter, J. R.; Ge, J.; Grenier,
L.; Pak, R. H.; Ali, J. A.; Dembski, M. S.; Hudak, J.; Patterson, J.;
Penders, C.; Pink, M.; Read, M. A.; Sang, J.; Woodward, C.;
Zhang, Y.; Grayzel, D. S.; Wright, J.; Barrett, J. A.; Palombella,
V. J.; Adams, J.; Tong, J. K. Development of 17-allylamino-17-
demethoxygeldanamycin hydroquinone hydrochloride (IPI-504),
an anticancer agent directed against Hsp90. Proc. Natl. Acad. Sci.
U.S.A. 2006, 103, 17408–17413.
(35) Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D.
B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; Cropp,
G. F.; Johnson, R. G.; Hannah, A. L.; Hudis, C. A. Combination
of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and
active in trastuzumab-refractory HER-2-overexpressing breast
cancer: a phase I dose-escalation study. J. Clin. Oncol. 2007, 25,
5410–5417.
(16) Delmotte, P.; Delmotte-Plaque, J. A new antifungal substance of
fungal origin. Nature 1953, 171, 344.
(17) Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S. V. Development of
radicicol analogues. Curr. Cancer Drug Targets 2003, 3, 359–369.
(18) Roe, S. M.; Prodromou, C.; O’Brien, R.; Ladbury, J. E.; Piper, P.
W.; Pearl, L. H. Structural basis for inhibition of the Hsp90
molecular chaperone by the antitumor antibiotics radicicol and
geldanamycin. J. Med. Chem. 1999, 42, 260–266.
(19) Hostein, I.; Robertson, D.; DiStefano, F.; Workman, P.; Clarke,
P. A. Inhibition of signal transduction by the Hsp90 inhibitor 17-
allylamino-17-demethoxygeldanamycin results in cytostasis and
apoptosis. Cancer Res. 2001, 61, 4003–4009.
(20) Schulte, T. W.; Neckers, L. M. The benzoquinone ansamycin 17-
allylamino-17-demethoxygeldanamycin binds to HSP90 and
shares important biologic activities with geldanamycin. Cancer
Chemother. Pharmacol. 1998, 42, 273–279.
(21) Banerji, U.; O’Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.;
Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.;
Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. Phase
I pharmacokinetic and pharmacodynamic study of 17-allylamino,
17-demethoxygeldanamycin in patients with advanced malignan-
cies. J. Clin. Oncol. 2005, 23, 4152–4161.
(36) Drysdale, M. J.; Brough, P. A. Medicinal chemistry of Hsp90
inhibitors. Curr. Top. Med. Chem. 2008, 8, 859–868.
(37) Chiosis, G. Discovery and development of purine-scaffold Hsp90
inhibitors. Curr. Top. Med. Chem. 2006, 6, 1183–1191.
(38) Chiosis, G.; Rodina, A.; Moulick, K. Emerging Hsp90 inhibitors:
from discovery to clinic. Anticancer Agents Med. Chem. 2006, 6,
1–8.
(39) Chiosis, G.; Lopes, E. C.; Solit, D. Heat shock protein-90 inhibi-
tors: a chronicle from geldanamycin to today’s agents. Curr. Opin.
Invest. Drugs (Thomson Scientific) 2006, 7, 534–541.
(22) Goetz, M. P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren,
S.; Adjei, A. A.; Sloan, J.; Atherton, P.; Vasile, V.; Salazaar, S.;
Adjei, A.; Croghan, G.; Erlichman, C. Phase I trial of 17-allylami-
no-17-demethoxygeldanamycin in patients with advanced cancer.
J. Clin. Oncol. 2005, 23, 1078–1087.
(23) Weigel, B. J.; Blaney, S. M.; Reid, J. M.; Safgren, S. L.; Bagatell, R.;
Kersey, J.; Neglia, J. P.; Ivy, S. P.; Ingle, A. M.; Whitesell, L.;
Gilbertson, R. J.; Krailo, M.; Ames, M.; Adamson, P. C. A Phase I
Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pe-
diatric Patients with Solid Tumors: A Children’s Oncology Group
Study. Clin. Cancer Res. 2007, 13, 1789–1793.
(40) Dymock, B. W.; Drysdale, M. J.; McDonald, E.; Workman, P.
Inhibitors of HSP90 and other chaperones for the treatment of
cancer. Expert Opin. Ther. Pat. 2004, 14, 837–847.
(41) Neckers, L.; Neckers, K. Heat-shock protein 90 inhibitors as novel
cancer chemotherapeutics;an update. Expert Opin. Emerging
Drugs 2005, 10, 137–149.
(42) Janin, Y. L. Heat shock protein 90 inhibitors. A text book example
of medicinal chemistry?. J. Med. Chem. 2005, 48, 7503–7512.
(43) Drysdale, M. J.; Brough, P. A.; Massey, A.; Jensen, M. R.;
Schoepfer, J. Targeting Hsp90 for the treatment of cancer. Curr.
Opin. Drug Discovery Dev. 2006, 9, 483–495.
(24) Solit, D. B.; Osman, I.; Polsky, D.; Panageas, K. S.; Daud, A.;
Goydos, J. S.; Teitcher, J.; Wolchok, J. D.; Germino, F. J.; Krown,
S. E.; Coit, D.; Rosen, N.; Chapman, P. B. Phase II Trial of 17-
Allylamino-17-Demethoxygeldanamycin in Patients with Meta-
static Melanoma. Clin. Cancer Res. 2008, 14, 8302–8307.
(25) Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.;
Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90
confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425,
407–410.
(26) da Rocha, D. S.; Friedlos, F.; Light, Y.; Springer, C.; Workman,
P.; Marais, R. Activated B-RAF is an Hsp90 client protein that is
targeted by the anticancer drug 17-allylamino-17-demethoxygel-
danamycin. Cancer Res. 2005, 65, 10686–10691.
(27) Workman, P.; Burrows, F.; Neckers, L. Drugging the cancer
chaperone HSP90: combinatorial therapeutic exploitation of on-
cogene addiction and tumor stress. Ann. N.Y. Acad. Sci. 2007, 1113,
202–216.
(28) Egorin, M. J.; Rosen, D. M.; Wolff, J. H.; Callery, P. S.; Musser, S.
M.; Eiseman, J. L. Metabolism of 17-(allylamino)-17-demethox-
ygeldanamycin (NSC 330507) by murine and human hepatic
preparations. Cancer Res. 1998, 58, 2385–2396.
(44) McDonald, E.; Workman, P.; Jones, K. Inhibitors of the HSP90
molecular chaperone: attacking the master regulator in cancer.
Curr. Top. Med. Chem. 2006, 6, 1091–1107.
(45) Messaoudi, S.; Peyrat, J. F.; Brion, J. D.; Alami, M. Recent
advances in Hsp90 inhibitors as antitumor agents. Anti-Cancer
Agents Med. Chem. 2008, 8, 761–782.
(46) Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting
Hsp90: small-molecule inhibitors and their clinical development.
Curr. Opin. Pharmacol. 2008, 8, 370–374.
(47) Taldone, T.; Sun, W.; Chiosis, G. Discovery and development of
heat shock protein 90 inhibitors. Bioorg. Med. Chem. 2009, 17,
2225–2235.
(48) Kasibhatla, S. R.; Hong, K.; Biamonte, M. A.; Busch, D. J.;
Karjian, P. L.; Sensintaffar, J. L.; Kamal, A.; Lough, R. E.;
Brekken, J.; Lundgren, K.; Grecko, R.; Timony, G. A.; Ran, Y.;
Mansfield, R.; Fritz, L. C.; Ulm, E.; Burrows, F. J.; Boehm, M. F.
Rationally designed high-affinity 2-amino-6-halopurine heat
shock protein 90 inhibitors that exhibit potent antitumor activity.
J. Med. Chem. 2007, 50, 2767–2778.
(49) Lundgren, K.; Zhang, H.; Brekken, J.; Huser, N.; Powell, R. E.;
Timple, N.; Busch, D. J.; Neely, L.; Sensintaffar, J. L.; Yang, Y. C.;
McKenzie, A.; Friedman, J.; Scannevin, R.; Kamal, A.; Hong, K.;
Kasibhatla, S. R.; Boehm, M. F.; Burrows, F. J. BIIB021, an orally
(29) Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Work-
man, P. DT-Diaphorase expression and tumor cell sensitivity to 17-